Targets › GPR55
1 program from 1 company in 1 trial: 1 Phase 1; Psychiatry; next expected readout Dec 2026.
G protein-coupled receptor that binds to several ligands including 2-arachidonoyl lysophosphatidylinositol or lysophosphatidylglucoside with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Induces the Ca(2+) release from intracellular stores via ERK, the heterotrimeric G protein GNA13 and RHOA leading to morphological changes including cell rounding and stress…. (UniProt, Q9Y2T6)
Open in Phaseline: the race on GPR55, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Universidade do Sul de Santa Catarina | Full-spectrum CBG oil 30 mg/mL Full-spectrum Cannabis extract containing cannabigerol (CBG), cannabidiol (CBD), and tetra | CNR1, CNR2, GPR55 | Phase 1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Dec 2026 |
Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.